Mochi Health and the State Pharmacy Investigation: What Patients Need to Know

What This Guide Covers

In May 2026, King5 — Seattle’s NBC affiliate — aired a report on a state pharmacy investigation reportedly involving Mochi Health, one of the higher-profile telehealth weight management platforms operating in the GLP-1 space. Community response to the report has been significant, with current and prospective Mochi patients asking what the investigation means for them and what, if anything, they should do.

This guide is consumer information, not legal advice, and it is written for patients — not as a verdict on Mochi Health. The underlying investigation, as of this writing, may be ongoing. Reported allegations are not adjudicated facts. A state pharmacy investigation is a serious matter worth taking seriously, and it is also worth being precise about what is known, what is alleged, and what remains to be determined.

What this guide covers: what King5 reportedly found, what the corporate context is, what pharmacy violations typically mean for patients as a legal and practical matter, what current patients may want to do, and how to file a complaint if you believe you have been harmed.

What King5 Reported

King5, the NBC affiliate serving the Seattle metropolitan area, reported in May 2026 on what it described as a state pharmacy investigation into Mochi Health’s prescription dispensing practices. According to the King5 reporting, the investigation reportedly identified concerns about how Mochi Health dispensed compounded GLP-1 prescriptions to patients.

The specific nature of the reported violations — and the precise regulatory findings, if any, from the state pharmacy board — were described in the King5 report. Because this guide is providing a secondary summary of that reporting rather than independent access to the underlying regulatory record, patients seeking the most complete account of what was reported should review the King5 broadcast and associated published coverage directly.

What is clear from the reporting, and consistent with the pattern of scrutiny that has followed compounded GLP-1 telehealth platforms broadly, is that the manner in which platforms handle the dispensing and compounding of GLP-1 medications has become a focus of regulatory attention across multiple states. Mochi Health, according to the King5 reporting, became the subject of such attention in the state of Washington.

Mochi Health and LifeMD: Context

Mochi Health launched as an independent telehealth weight management platform that connected patients with licensed prescribers for compounded GLP-1 medications, primarily compounded semaglutide and tirzepatide. It positioned itself in the direct-to-consumer telehealth weight loss market alongside competitors such as Hims & Hers, LifeMD’s legacy programs, TrimRx, Eden Health, and others.

In 2024, Mochi Health was acquired by LifeMD, Inc., a publicly traded telehealth company. Following the acquisition, Mochi Health operated as part of LifeMD’s broader telehealth portfolio. This corporate relationship is relevant to patients for two reasons.

LifeMD’s Separate Consumer Billing Complaints

In 2025 and 2026, LifeMD — as the parent entity — faced consumer complaints and regulatory attention regarding billing practices that were separate from, but related to, the Mochi Health pharmacy investigation. According to reports in this period, consumer billing complaints involving LifeMD-associated programs included allegations of charges continuing after cancellation, difficulty canceling subscriptions, and unauthorized plan upgrades. These complaints followed patterns consistent with those documented across the broader telehealth GLP-1 market in the same period.

The FTC, which has authority over deceptive practices and negative option billing schemes, has been an active presence in the telehealth GLP-1 billing space during this period. Whether LifeMD or Mochi Health has been the subject of formal FTC attention as of this writing is a matter of public record that patients can look up directly at the FTC’s public enforcement database.

What the LifeMD Relationship Means for Patients

For current Mochi Health patients, the LifeMD relationship means that complaints, billing issues, and records requests may need to navigate both Mochi Health’s own customer service infrastructure and LifeMD’s corporate structure. If you are having difficulty obtaining records or resolving a billing issue through Mochi Health directly, escalating to LifeMD as the parent company may be appropriate. LifeMD is a publicly traded company; its investor relations and regulatory filings are public documents that can provide context about how the company has characterized the pharmacy investigation and any related regulatory matters.

What Pharmacy Violations Typically Mean for Patients

State pharmacy boards regulate how prescriptions are written, compounded, filled, and dispensed within their jurisdiction. Understanding what types of violations state boards investigate — and what their practical implications are for patients — is essential context for evaluating what the King5 reporting means.

Common Categories of Pharmacy Violations

State pharmacy board investigations in the compounded GLP-1 space have, across multiple cases in this period, focused on several categories of potential violations. These are described here generally, not as a characterization of what Mochi Health specifically was found to have done.

• Dispensing without a valid prescription. Medications requiring a prescription must be dispensed pursuant to a valid prescription issued by a licensed prescriber who has established a legitimate prescriber-patient relationship. Dispensing without a valid prescription — including prescriptions issued through a process that does not meet clinical standards — is a fundamental pharmacy compliance requirement.
• Improper compounding practices. Compounded GLP-1 medications must be prepared in accordance with applicable USP standards and state pharmacy board rules. Violations in this category can include sterility failures, incorrect potency, use of unapproved API forms, and failure to conduct required quality testing.
• Dispensing outside the scope of license. A pharmacy licensed in one state may have limitations on its ability to dispense medications to patients in other states. Telehealth platforms that use a single pharmacy to ship to patients nationwide have created compliance challenges in this area.
• Record-keeping failures. State pharmacy boards require specific records for every prescription filled. Failures to maintain adequate records are a distinct category of violation with their own remedies.
• Failure to verify prescription validity. A dispensing pharmacy has an independent obligation to verify that a prescription appears valid before filling it. This is separate from the prescriber’s obligation.

What Violations Can Mean for Patients

If a pharmacy is found to have committed violations of the type described above, the implications for patients depend on which type of violation occurred and its severity.

• ▶
  Medication safety concerns. If violations involved compounding practices — sterility, potency, contamination — the most direct patient concern is whether the medications received were safe and effective. Patients who experienced unexpected side effects or lack of efficacy during the relevant period may want to consult with their physician about whether those experiences could be related.
• ▶
  Prescription validity questions. If violations involved the prescription issuance process, patients may have questions about whether their prescriptions were legally valid. A prescription issued without a legitimate prescriber-patient relationship may be legally problematic even if the medication itself was properly compounded. Patients who need to document a valid prescription for transition to another provider should consult with their physician.
• ▶
  Program continuity risk. A state pharmacy board can take actions ranging from a warning letter to a consent agreement to license suspension or revocation. If a license action is taken against the pharmacy dispensing Mochi Health prescriptions, that pharmacy may be unable to continue filling prescriptions. Patients relying on Mochi Health for ongoing GLP-1 therapy should have a backup plan — specifically, a relationship with a prescribing provider who could continue their care through a different pharmacy if needed.
• ▶
  Refund and billing implications. Depending on the nature of any violations found, patients who received medication dispensed in violation of pharmacy law may have consumer protection claims for billing related to those shipments. This is a fact-specific legal question; the analysis depends on the specific violations found and the governing law. If this concern applies to you, a consumer protection attorney in your state is the appropriate resource.

The Broader Pattern: Telehealth GLP-1 Issues in 2025–2026

Context matters here, both for calibrating the seriousness of what is being reported and for understanding what it means for the broader telehealth GLP-1 market. Mochi Health is not an isolated case.

In 2025 and into 2026, a consistent pattern of consumer complaints and regulatory attention has followed multiple telehealth GLP-1 platforms. The pattern is worth documenting, not to create the impression that the entire category is fraudulent — it is not — but because patients benefit from understanding the landscape they are navigating.

Platforms With Reported Issues in This Period

• LifeMD / Mochi Health. As described above: the King5-reported pharmacy investigation (May 2026), plus consumer billing complaints related to post-cancellation charges and subscription management. LifeMD is the parent company; Mochi Health is its weight management program.
• TrimRx. Consumer billing complaints in this period have described post-cancellation charges and difficulty obtaining refunds following the 2025 FDA crackdown on compounded semaglutide and tirzepatide, which prompted abrupt program changes for patients mid-subscription.
• Eden Health. Eden, a telehealth GLP-1 platform, generated consumer billing complaints in the same period. Community reports described overlapping patterns: charges continuing after confirmed cancellation, difficulty reaching customer service during disputes. Eden was among the platforms named in community monitoring of GLP-1 billing concerns during this period.
• Fitrxapp. Consumer billing complaints related to Fitrxapp have been reported in this period, with similar patterns to those described above.

For patients evaluating any telehealth GLP-1 platform — including those not named here — the GLP-1 Telehealth Provider Vetting Guide on this site provides a detailed pre-enrollment checklist, red flag criteria, and a framework for applying appropriate skepticism before providing payment information.

What Current Mochi Health Patients Should Consider Doing

If you are currently enrolled in Mochi Health and are trying to figure out what to do following the King5 report, the following steps are framed as practical suggestions rather than legal advice. The right course of action for any individual patient depends on their circumstances, and the following is not a substitute for consulting with your own physician.

1. 1
   Verify your current prescription status. Contact Mochi Health through its platform to confirm whether your prescription is currently active and whether your next shipment is scheduled as expected. Ask specifically which pharmacy is dispensing your medication. If the pharmacy has changed recently, ask when the change occurred and why.
2. 2
   Verify the dispensing pharmacy’s license. Once you know which pharmacy is filling your prescription, verify that pharmacy’s license through your state pharmacy board’s public license lookup. Most state boards have searchable online databases. Confirm the pharmacy is currently licensed to dispense in your state.
3. 3
   Ensure your prescription was issued through a legitimate clinical process. A valid GLP-1 prescription requires a licensed prescriber who has established a legitimate prescriber-patient relationship and conducted an adequate clinical assessment. If your onboarding consisted entirely of a questionnaire with no synchronous consultation with a licensed provider, that is worth raising with a physician. This is not a legal verdict — asynchronous prescribing is lawful in many states under certain conditions — but it is a clinical quality question worth evaluating if you are uncertain.
4. 4
   Review your billing and payment records. Review your card statements for the past 90–120 days. Confirm that every charge from Mochi Health or LifeMD is for a service or shipment you authorized at the amount you authorized. If you identify any unauthorized charges or charges that continued after a cancellation request, document them now (see Section 8).
5. 5
   Request and save your medical records. Under HIPAA, you have the right to request copies of your medical records from Mochi Health. Submit a written request through the platform’s secure messaging system or by email, requesting all prescription records, consultation notes, and any other records related to your care. Save the request and any response. Having your records gives you the ability to transition your care to another provider without losing your clinical history.
6. 6
   Establish a continuity plan for your medication. If you are currently receiving GLP-1 medication through Mochi Health and are concerned about program continuity, now is a reasonable time to establish or re-establish a relationship with a primary care provider or an endocrinologist who could continue your care through a different prescribing pathway if needed. This is not a prediction that Mochi Health will be unable to continue operating — it is prudent care continuity planning.
7. 7
   Monitor for communications from Mochi Health. Following a regulatory development of this nature, patients should expect to receive communications from Mochi Health addressing the King5 report and any steps the company is taking. Read these communications carefully and be cautious of representations that minimize the severity of what was reported. You are entitled to clear, accurate information about the status of the program that is managing your medication.

If You Are Considering Starting Mochi Health

Prospective patients who were evaluating Mochi Health before the King5 report are in a different position than current patients. You have not yet provided payment information, established a prescribing relationship, or received medication. Your decision is forward-looking.

The reasonable question is: should I wait?

The honest answer is that the situation, as of this writing, has not been fully resolved. The investigation that King5 reported on may be ongoing. The specific findings, if any, from the state pharmacy board may not yet be publicly available in their final form. In that environment of incomplete information, patients considering enrolling have a few options.

• ▶
  Wait for resolution clarity. If you are not in immediate medical need of a GLP-1 medication through a telehealth platform — if you have time to evaluate the situation as it develops — waiting for the investigation to reach a publicly documented resolution is a reasonable approach. Regulatory investigations that result in significant findings typically produce public records: consent agreements, license actions, or final orders that are searchable through the relevant state pharmacy board.
• ▶
  Apply the vetting checklist to Mochi specifically. Before enrolling with any telehealth GLP-1 platform, apply the pre-enrollment vetting questions from the GLP-1 Telehealth Provider Vetting Guide: Which pharmacy fills my prescription? Can I verify that pharmacy’s license? What is the cancellation policy? Can I get a Certificate of Analysis? What does the prescribing process look like? These questions are appropriate for any platform — but in the current context, the answers Mochi Health provides are particularly worth evaluating carefully.
• ▶
  Consider alternative platforms while you evaluate. The GLP-1 telehealth market includes multiple platforms. Our vetting guide provides a framework for comparing them, and our compounding crackdown guide covers how the 2025 FDA actions affected platform operations. Evaluating alternatives in parallel while you monitor the Mochi Health situation is a reasonable approach.
• ▶
  Consider a conventional care pathway. A primary care physician or endocrinologist who prescribes GLP-1 medications through a conventional pharmacy relationship offers a different risk profile than telehealth compounding programs. For patients with access to that pathway, it avoids the compounding compliance questions entirely. The GLP-1 program terms guide covers the range of program structures available.

How to File a Complaint

If you believe you have been harmed by Mochi Health — through unauthorized billing, unsafe medication, or violations of your patient rights — the following complaint avenues are available to you. Filing a complaint creates a record, may prompt regulatory attention, and in the case of billing disputes, can initiate a legal process that results in recovery of funds.

For Pharmacy Practice Concerns

• ▶
  Your state pharmacy board. If you have concerns about the pharmacy that dispensed your Mochi Health prescription — including concerns about the validity of your prescription, the quality of the medication you received, or the pharmacy’s license status — file a complaint with the state pharmacy board in the state where the dispensing pharmacy is licensed, and in your own state. Most state pharmacy boards have online complaint forms. Search “[your state] pharmacy board complaint” for the direct link.
• ▶
  Your state medical board. If you have concerns about the prescribing provider — including whether a legitimate clinical consultation occurred, or whether the prescriber is licensed in your state — file a complaint with your state medical board. Verify the prescriber’s license through the board’s public lookup before filing.

For Billing and Consumer Protection Concerns

• ▶
  The FTC at reportfraud.ftc.gov. The Federal Trade Commission accepts consumer complaints about unfair or deceptive business practices, including unauthorized billing, negative option violations, and subscription fraud. File at reportfraud.ftc.gov. Individual complaints may not generate immediate individual relief, but complaint volume informs FTC enforcement prioritization.
• ▶
  Your state Attorney General’s consumer protection division. Every state has a consumer protection division within the AG’s office. Complaints filed there create a record and contribute to patterns that may prompt state-level investigation or action. Search “[your state] attorney general consumer protection complaint” for the direct link.
• ▶
  Your credit card issuer (FCBA dispute). If Mochi Health charged you after a confirmed cancellation, or charged you for a service you did not authorize, dispute the charge under the Fair Credit Billing Act. You have 60 days from the statement containing the unauthorized charge. Your issuer is required to investigate and provisionally credit your account during the investigation. For a detailed guide to this process, see the billing dispute section of the GLP-1 Telehealth Vetting Guide.
• ▶
  The Better Business Bureau. BBB complaints are less formal but create a visible public record. They also have a structured response process that sometimes generates faster direct resolution than other channels. A visible BBB complaint record also informs prospective patients researching the company.

The Regulatory Gap That Enables These Patterns

Understanding why the Mochi Health situation — and the broader pattern of telehealth GLP-1 issues in this period — has unfolded as it has requires understanding a structural feature of how these platforms exist in the regulatory landscape.

Telehealth GLP-1 platforms operate in an environment where three separate regulatory frameworks apply to different aspects of their operations, with no single body having comprehensive jurisdiction over the platform as an integrated business.

The clinical prescribing practice of the providers is regulated by state medical boards. The compounding pharmacy is regulated by state pharmacy boards and, for 503B outsourcing facilities, by the FDA. The billing and subscription practices of the platform are subject to FTC authority over deceptive and unfair practices, and to state consumer protection law. But no single regulator actively vets a telehealth GLP-1 platform before it begins operating, none has real-time visibility into its pharmacy partnerships, and enforcement in each domain is reactive rather than prospective.

The 2025 FDA crackdown on compounded semaglutide and tirzepatide created a sudden, significant operational disruption for platforms built around those compounds. Platforms that had enrolled patients in ongoing subscriptions had to restructure their pharmacy relationships rapidly, often without clear patient communication, and in some cases under business pressure that created compliance shortcuts. State pharmacy boards, operating with limited investigative bandwidth, are working through the consequences of that disruption now.

This is not unique to Mochi Health. It is a structural issue, and patients are the most effective first line of protection. The regulatory gap means there is no government agency proactively vetting your telehealth pharmacy before your medication ships. The framework for patient protection — FCBA dispute rights, state AG complaints, pharmacy board oversight — exists and has real teeth. But it activates after something has gone wrong, not before.

The practical response to this structural reality is the same as it has always been in underregulated markets: pre-signup due diligence, documentation of your enrollment and cancellation, use of a credit card rather than a debit card, and awareness of your complaint rights before you need them. The GLP-1 Telehealth Provider Vetting Guide is the companion to this article and provides the pre-enrollment framework in detail.

Frequently Asked Questions